# A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

> **NCT05873764** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 9 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** 200 mg RV521/78 µCi [ 14C]-RV521.

## Key facts

- **NCT ID:** NCT05873764
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-25
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-07-12
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05873764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05873764, "A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05873764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*